Evolent Health filings document the regulatory disclosures of a healthcare services company focused on complex specialty care and value-based care infrastructure. Its 8-K reports cover operating and financial results, material agreements, capital-structure matters, completed subsidiary transactions, and compensation arrangements tied to executive appointments.
Proxy materials disclose annual meeting matters, board oversight, director elections, executive compensation, and governance practices. Other current reports record board and officer transitions, equity incentives, and corporate events affecting Evolent Health, Inc. and its wholly owned subsidiary structure.
Ajayi Toyin reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. reported that director Dr. Toyin Ajayi received an equity grant of 41,096 shares of Class A common stock in the form of restricted stock units under the company’s 2015 Omnibus Incentive Compensation Plan. After this award, Dr. Ajayi directly holds 75,170 shares. These restricted stock units vest on the earlier of June 4, 2027, or the date of Evolent Health’s 2027 annual meeting, assuming she continues to serve through the vesting date.
Glass Russell Monroe reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Russell Monroe Glass reported an equity award of 41,096 shares of Class A Common Stock in the form of restricted stock units granted at $0.00 per share under the company’s 2015 Omnibus Incentive Compensation Plan. These RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual meeting, subject to his continued service. Following the award, he directly owns 77,347 shares and indirectly holds 6,046 shares through a trust he and his spouse co‑trustee and over which they share voting and dispositive power.
GRUA PETER J reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Peter J. Grua reported a compensation-related equity grant rather than an open-market trade. He received 41,096 shares of Class A Common Stock in the form of restricted stock units at $0.00 per share under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. These securities vest on the earlier of June 4, 2027 and the date of the company’s 2027 annual meeting, subject to his continued service. Following the grant, he directly holds 63,075 shares, and a trust for his sole benefit holds an additional 60,668 shares over which he has sole voting and dispositive power.
GUERTIN SHAWN M reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Shawn M. Guertin received an equity award of 41,096 shares of Class A Common Stock in the form of restricted stock units granted at no cash cost to him. These units were issued under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
The restricted stock units vest on the earlier of June 4, 2027, and the date of the company’s 2027 annual meeting, subject to his continued service through the vesting date. Following this award, Guertin directly holds 63,075 shares of Evolent Health Class A Common Stock.
Jelinek Richard M reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Richard M. Jelinek reported an equity award of Class A common stock. He received 41,096 restricted stock units at no purchase price under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan. These units vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, if he continues serving through that date.
After the award, he holds 77,533 shares of Class A common stock directly, with additional 15,000-share positions shown in each of two trusts as indirect holdings.
KECK KIM reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health director Kim Keck received an equity grant that increases her direct ownership stake. She was awarded 41,096 shares of Class A Common Stock in the form of restricted stock units under the company’s 2015 Omnibus Incentive Compensation Plan, bringing her direct holdings to 102,597 shares. These units vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, as long as she continues serving on the board.
Evolent Health, Inc. director Jill D. Smith reported an equity compensation grant. She acquired 41,096 shares of Class A Common Stock in the form of restricted stock units granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
The securities vest on the earlier of June 4, 2027 or the company’s 2027 annual meeting, contingent on her continued service through the vesting date. Following this award, Smith holds 64,233 shares of Evolent Health common stock directly.
Springstubb Brendan B reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. director Brendan B. Springstubb received a grant of 41,096 shares of Class A Common Stock in the form of restricted stock units at a price of $0.00 per share. Following this equity award, he holds 99,917 shares directly. The restricted stock units were granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan and will vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, subject to his continued service.
Barbarosh Craig A. reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health director Craig A. Barbarosh received an equity grant of 41,096 restricted stock units of Class A Common Stock. The award was made at no cash cost to him as part of Evolent Health’s 2015 Omnibus Incentive Compensation Plan. These units are scheduled to vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, contingent on his continued board service. Following this grant, he directly holds 95,031 shares of Class A Common Stock.
Evolent Health, Inc. reported the results of its 2026 annual stockholder meeting held on June 4, 2026. Stockholders elected ten director nominees to one-year terms ending at the 2027 annual meeting. Each nominee received significantly more votes “for” than “against,” with substantial broker non-votes recorded.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. An advisory vote approved 2025 compensation for named executive officers, and investors approved an amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan, supporting the company’s executive pay and equity incentive framework.